News
GSK co-leads investment in ‘disease rebalancing’ Adrestia Therapeutics
GlaxoSmithKline, alongside Ahren Innovation Capital, will co-lead series A investment in UK-based biotech company Adrestia Therapeutics.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
GlaxoSmithKline, alongside Ahren Innovation Capital, will co-lead series A investment in UK-based biotech company Adrestia Therapeutics.